Nanologica will be attending BIO-Europe in Hamburg, Nov. 11-13, to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™. Nanologica’s drug delivery platform NLAB Silica™ consists of nanoporous amorphous proprietary silica particles. By loading ...Läs merNanologica to attend BIO-Europe Nov. 11-13 in Hamburg for partnering discussions

‍